Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

3-Iodobenzylguanidine 5Doxorubicin 3cabozantinib 2Temozolomide 2Radiotherapy 2Phenoxybenzamine 2Ifosfamide 2Filgrastim 2Everolimus 2Doxazosin 2Dexmedetomidine 2vatalanib 1temsirolimus 1pegfilgrastim 1lenvatinib 1fostamatinib 1atezolizumab 1anlotinib 1Vinorelbine 1Tamoxifen 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Saline Solution 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pheochromocytoma × cabozantinib × Clear all
NCT02302833 2025-07-31

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Completed
21 enrolled 7 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡